GKIM
IMDX

GW&K Investment Management’s Insight Molecular Diagnostics IMDX Stock Holding History

GW&K Investment Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-39,089
Closed -$2.78M – 393
2021
Q3 		$2.78M Buy
39,089
+217
+0.6% +$19.9K 0.02% 309
2021
Q2 		$4.46M Hold
38,872
– – 0.04% 289
2021
Q1 		$4.04M Buy
+38,872
New +$3.69M 0.04% 296

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

GW&K Investment Management's IMDX Position: Q4 2021 in Review

GW&K Investment Management sold out of Insight Molecular Diagnostics (IMDX) in Q4 2021, closing a stake of 39,089 shares — an estimated $2.78M sold.

GW&K Investment Management first reported a position in IMDX in Q1 2021 and held it in 3 quarters. The position peaked at $4.46M in Q2 2021. 88 funds tracked by Wall St. Rank hold IMDX as of Q4 2021.

  • GW&K Investment Management reported no remaining Insight Molecular Diagnostics position as of Q4 2021 after selling out during the quarter.
  • GW&K Investment Management sold 39,089 Insight Molecular Diagnostics shares in Q4 2021, an estimated $2.78M.
  • GW&K Investment Management first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 3 quarters.
  • GW&K Investment Management's Insight Molecular Diagnostics position peaked at $4.46M in Q2 2021.
  • 88 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2021.

Based on GW&K Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.